Intech Investment Management LLC Buys 20,795 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Intech Investment Management LLC lifted its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 121.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,902 shares of the company's stock after acquiring an additional 20,795 shares during the period. Intech Investment Management LLC owned 0.05% of Akero Therapeutics worth $1,054,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Summit Financial Wealth Advisors LLC acquired a new stake in Akero Therapeutics in the third quarter worth approximately $205,000. Victory Capital Management Inc. bought a new stake in Akero Therapeutics in the third quarter worth about $211,000. AlphaQuest LLC lifted its holdings in Akero Therapeutics by 32,588.0% in the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after acquiring an additional 8,147 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Akero Therapeutics during the 3rd quarter valued at about $265,000. Finally, XTX Topco Ltd acquired a new position in shares of Akero Therapeutics in the 3rd quarter worth approximately $308,000.

Akero Therapeutics Stock Down 4.3 %

AKRO stock traded down $1.95 during midday trading on Wednesday, reaching $43.29. The company had a trading volume of 690,685 shares, compared to its average volume of 807,384. The company has a 50 day moving average of $44.85 and a two-hundred day moving average of $34.78. The company has a market capitalization of $3.45 billion, a P/E ratio of -11.54 and a beta of -0.19. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Remove Ads

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). On average, equities research analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Citigroup lifted their target price on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and upped their target price for the company from $35.00 to $63.00 in a report on Thursday, January 30th. UBS Group lifted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Finally, HC Wainwright lifted their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $76.29.

Insider Buying and Selling

In related news, VP Patrick Lamy sold 5,000 shares of Akero Therapeutics stock in a transaction on Monday, January 27th. The shares were sold at an average price of $57.03, for a total value of $285,150.00. Following the completion of the sale, the vice president now owns 33,492 shares of the company's stock, valued at approximately $1,910,048.76. The trade was a 12.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Timothy Rolph sold 18,750 shares of the company's stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $56.51, for a total transaction of $1,059,562.50. Following the completion of the sale, the insider now owns 170,237 shares of the company's stock, valued at $9,620,092.87. This represents a 9.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 252,135 shares of company stock worth $12,345,079. Insiders own 7.94% of the company's stock.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.